RxDoctor Payments Data

Mark Shikowitz, MD

Otolaryngology · New Hyde Park, NYNPI 1104997105

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Neurent Medical Limited at 41.5% of the total. Reporting peaked in 2023 at $1,556 and has fallen 98.8% since, to $19 in 2025.

$2,714in general payments, 2019–2025

Across 25 payments — averaging $108.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurent Medical Limited$1K
  • Acclarent, Inc$443
  • Inspire Medical Systems, Inc.$396
  • Intersect ENT, Inc.$295
  • Aerin Medical Inc.$290
  • Stryker$136
  • plus $28 from 1 others
$28,264in research payments, 2019–2025

Across 11 payments — averaging $2569.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biohaven Pharmaceutical Holding Company Ltd.$24K
  • Roche Products Limited$4K

What the payments were for

  • Food & beverage$2,714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,714 in reported general payments places this provider in the 65th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York

Medicare billing

Part B allowed, 2024
$143,225
Medicare patients
220
Services billed
704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mometasone Furoate29$1,600
Fluticasone Propionate118$985
Fluocinolone Acetonide Oil14$666
Azelastine Hcl32$551
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$124
Methylprednisolone15$65
Omeprazole12$47

Paid to pharmacies, not to this prescriber.

Other otolaryngology in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →